Search

Your search keyword '"Mohammadi, Pantea"' showing total 29 results
Start Over Author "Mohammadi, Pantea"
29 results on '"Mohammadi, Pantea"'

11. Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases

Author

Hesari, Mahvash, Mohammadi, Pantea, Khademi, Fatemeh, Shackebaei, Dareuosh, Momtaz, Saeideh, Moasefi, Narges, Farzaei, Mohammad Hosein, and Abdollahi, Mohammad

Subjects
medicine.medical_specialty, Combination therapy, natural products, Biophysics, Pharmaceutical Science, Bioengineering, Context (language use), Review, 02 engineering and technology, 010402 general chemistry, 01 natural sciences, Biomaterials, chemistry.chemical_compound, Drug Discovery, Humans, Medicine, Adverse effect, Intensive care medicine, Plants, Medicinal, Mechanism (biology), business.industry, Organic Chemistry, nanoformulation, General Medicine, 021001 nanoscience & nanotechnology, 0104 chemical sciences, Clinical trial, Nanomedicine, chemistry, Cardiovascular Diseases, Drug delivery, Curcumin, nanoparticles, Nanocarriers, 0210 nano-technology, business, medicinal plants
Abstract

Considering the high prevalence of cardiovascular diseases (CVDs), the primary cause of death during the last several decades, it is necessary to develop proper strategies for the prevention and treatment of CVDs. Given the excessive side effects of current therapies, alternative therapeutic approaches like medicinal plants and natural products are preferred. Lower toxicity, chemical diversity, cost-effectiveness, and proven therapeutic potentials make natural products superior compared to other products. Nanoformulation methods improve the solubility, bioavailability, circulation time, surface area-to-volume ratio, systemic adverse side effects, and drug delivery efficiency of these medications. This study intended to review the functionality of the most recent nanoformulated medicinal plants and/or natural products against various cardiovascular conditions such as hypertension, atherosclerosis, thrombosis, and myocardial infarction. Literature review revealed that curcumin, quercetin, and resveratrol were the most applied natural products, respectively. Combination therapy, conjugation, or fabrication of nanoparticles and nanocarriers improved the applications and therapeutic efficacy of herbal- or natural-based nanoformulations. In the context of CVDs prevention and/or treatment, available data suggest that natural-based nanoformulations are considerably efficient, alone or in blend with other herbal/synthetic medicines. However, clinical trials are mandatory to elucidate the safety, cardioprotective effect, and mechanism of actions of nanophytomedicines.

Published
2021

16. Nanoformulations of natural products for management of metabolic syndrome

Author

Taghipour, Yasamin Davatgaran, Hajialyani, Marziyeh, Naseri, Rozita, Hesari, Mahvash, Mohammadi, Pantea, Stefanucci, Azzurra, Mollica, Adriano, Farzaei, Mohammad Hosein, and Abdollahi, Mohammad

Subjects
Metabolic Syndrome, Translational Research, Biomedical, Biological Products, Plants, Medicinal, diabetes, natural products, Drug Compounding, Humans, Nanoparticles, Review, nanoformulation
Abstract

Metabolic syndrome is a common metabolic disorder which has become a public health challenge worldwide. There has been growing interest in medications including natural products as complementary or alternative choices for common chemical therapeutics regarding their limited side effects and ease of access. Nanosizing these compounds may help to increase their solubility, bioavailability, and promisingly enhance their efficacy. This study, for the first time, provides a comprehensive overview of the application of natural-products-based nanoformulations in the management of metabolic syndrome. Different phytochemicals including curcumin, berberine, Capsicum oleoresin, naringenin, emodin, gymnemic acid, resveratrol, quercetin, scutellarin, stevioside, silybin, baicalin, and others have been nanosized hitherto, and their nanosizing method and effect in treatment and alleviating metabolic syndrome have been reviewed and discussed in this study. It has been discovered that there are several pathways or molecular targets relevant to metabolic disorders which are affected by these compounds. Various natural-based nanoformulations have shown promising effect in treatment of metabolic syndrome, and therefore can be considered as future candidates instead of or in conjunction with pharmaceutical drugs if they pass clinical trials successfully.

Published
2019

18. Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases

Author

Hesari,Mahvash, Mohammadi,Pantea, Khademi,Fatemeh, Shackebaei,Dareuosh, Momtaz,Saeideh, Moasefi,Narges, Farzaei,Mohammad Hosein, Abdollahi,Mohammad, Hesari,Mahvash, Mohammadi,Pantea, Khademi,Fatemeh, Shackebaei,Dareuosh, Momtaz,Saeideh, Moasefi,Narges, Farzaei,Mohammad Hosein, and Abdollahi,Mohammad

Abstract

Mahvash Hesari,1 Pantea Mohammadi,1 Fatemeh Khademi,1 Dareuosh Shackebaei,1 Saeideh Momtaz,2– 5 Narges Moasefi,1 Mohammad Hosein Farzaei,6 Mohammad Abdollahi3,4 1Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Tehran, Iran; 3Toxicology and Diseases Group, Pharmaceutical Sciences Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; 4Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 5Gastrointestinal Pharmacology Interest Group, Universal Scientific Education and Research Network (USERN), Tehran, Iran; 6Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, IranCorrespondence: Mohammad Hosein FarzaeiMedical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, IranEmail mh.farzaei@gmail.comMohammad AbdollahiDepartment of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, 1417614411, IranEmail Mohammad@TUMS.Ac.IrAbstract: Considering the high prevalence of cardiovascular diseases (CVDs), the primary cause of death during the last several decades, it is necessary to develop proper strategies for the prevention and treatment of CVDs. Given the excessive side effects of current therapies, alternative therapeutic approaches like medicinal plants and natural products are preferred. Lower toxicity, chemical diversity, cost-effectiveness, and proven therapeutic potentials make natural products superior compared to other products. Nanoformulation methods improve the solubility, bioavailability, circulation time, surface area-to-volume ratio, systemic adverse side effects, and drug delivery efficiency of these medica

Published
2021

22. Irreversible thermal inactivation and conformational lock of alpha glucosidase

Author

Alaei, Loghman, primary, Izadi, Zhila, additional, Jafari, Samira, additional, Jahanshahi, Fatemeh, additional, Jaymand, Mehdi, additional, Mohammadi, Pantea, additional, Paray, Bilal Ahamad, additional, Hasan, Anwarul, additional, Falahati, Mojtaba, additional, Varnamkhasti, Behrang Shiri, additional, Saboury, Ali Akbar, additional, Moosavi-Nejad, Zahra, additional, Sheikh-Hosseini, Mehrnaz, additional, and Derakhshankhah, Hossein, additional

Published
2020
Full Text
View/download PDF

23. Nanoformulations of natural products for management of metabolic syndrome

Author

Davatgaran Taghipour,Yasamin, Hajialyani,Marziyeh, Naseri,Rozita, Hesari,Mahvash, Mohammadi,Pantea, Stefanucci,Azzurra, Mollica,Adriano, Farzaei,Mohammad Hosein, and Abdollahi,Mohammad

Subjects
International Journal of Nanomedicine
Abstract

Yasamin Davatgaran Taghipour,1–3 Marziyeh Hajialyani,4 Rozita Naseri,5 Mahvash Hesari,6 Pantea Mohammadi,6 Azzurra Stefanucci,7 Adriano Mollica,7 Mohammad Hosein Farzaei,4,6Mohammad Abdollahi81Department of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; 2Phytopharmacology Interest Group (PPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; 3Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 4Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 5Internal Medicine Department, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; 6Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; 7Department of Pharmacy, G. d’Annunzio University of Chieti-pescara, Chieti 66100, Italy; 8Toxicology and Diseases Group, the Institute of Pharmaceutical Sciences (TIPS) and Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, IranAbstract: Metabolic syndrome is a common metabolic disorder which has become a public health challenge worldwide. There has been growing interest in medications including natural products as complementary or alternative choices for common chemical therapeutics regarding their limited side effects and ease of access. Nanosizing these compounds may help to increase their solubility, bioavailability, and promisingly enhance their efficacy. This study, for the first time, provides a comprehensive overview of the application of natural-products-based nanoformulations in the management of metabolic syndrome. Different phytochemicals including curcumin, berberine, Capsicum oleoresin, naringenin, emodin, gymnemic acid, resveratrol, quercetin, scutellarin, stevioside, silybin, baicalin, and others have been nanosized hitherto, and their nanosizing method and effect in treatment and alleviating metabolic syndrome have been reviewed and discussed in this study. It has been discovered that there are several pathways or molecular targets relevant to metabolic disorders which are affected by these compounds. Various natural-based nanoformulations have shown promising effect in treatment of metabolic syndrome, and therefore can be considered as future candidates instead of or in conjunction with pharmaceutical drugs if they pass clinical trials successfully.Keywords: nanoformulation, natural products, metabolic syndrome, diabetes

Published
2019

25. The Antimicrobial Peptide, Nisin, Synergistically Enhances the Cytotoxic and Apoptotic Effects of Rituximab Treatment on Human Burkitt’s Lymphoma Cell Lines.

Author

Mohammadi, Pantea, Zangeneh, Mina, Mohammadi-Motlagh, Hamid-Reza, and Khademi, Fatemeh

Subjects
*BURKITT'S lymphoma, *TREATMENT effectiveness, *RITUXIMAB, *CD20 antigen, *CELL lines, *LYMPHOMAS, *NISIN, *CATHELICIDINS
Abstract

Background: Non-Hodgkin’s lymphomas comprise the most common hematological cancers worldwide and consist of a heterogenous group of malignancies affecting the lymphoid system. Treatment of non-Hodgkin’s lymphoma has been significantly enhanced with the addition of Rituximab to the standard chemotherapy regimen. However, even with the advancement of treatment patients continue to relapse and develop resistance to Rituximab, rendering subsequent treatments unsuccessful. The use of novel drugs with unique antitumor mechanisms has gained considerable attention. In this study, we explored the in vitro anti-cancer effects of the combined therapy of Rituximab and Nisin on human Burkitt’s lymphoma cells. Methods: The human Burkitt’s lymphoma cells lines, Raji and Daudi, were treated with Nisin, Rituximab, or a combination of the two agents at various concentrations. Cytotoxicity following treatment was determined using cell viability assay. The degree of apoptosis was verified via flow cytometric analysis using FITC annexin V/PI staining. Results: Our findings show that the combined treatment of Rituximab and Nisin results in a more significant reduction in the survival of Raji and Daudi Burkitt’s lymphoma cells, compared to Nisin or Rituximab treatment alone. Additionally, our results indicate that Nisin can induce a significant degree of apoptosis in the Burkitt’s lymphoma cells compared to the negative controls. However, the addition of Nisin to the Rituximab treatment synergistically enhances the apoptotic antitumor effect. Conclusions: This study demonstrates the synergistic antitumor effect of Nisin treatment in vitro to enhance tumor cell apoptosis and the potential value of Nisin as an adjunct therapy in the treatment of lymphoma. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

28. Isolation of Shiga toxin-producing Escherichia coli from raw milk in Kermanshah, Iran.

Author

Mohammadi, Pantea, Abiri, Ramin, Rezaei, Mansour, and Salmanzadeh-Ahrabi, Siavosh

Subjects
*VEROCYTOTOXINS, *ESCHERICHIA coli, *RAW milk, *MILK microbiology, *DIARRHEA
Abstract

Background and Objectives: Infectious diarrhoeal diseases are great problem throughout the world and are responsible for considerable morbidity and mortality. Shiga toxin-producing Escherichia coli (STEC) is a major cause of gastroenteritis that may be complicated by hemorrhagic colitis (HC) or the hemolytic uremic syndrome (HUS), which is the main cause of acute renal failure in children. Food-borne outbreaks associated with Shiga toxin-producing Escherichia coli have been well documented worldwide. The aim of this study was to investigate the prevalence of Shiga toxin-producing Escherichia coli (STEC) strains in raw milk samples. Materials and Methods: Raw milk samples collected from various cow farms in Kermanshah, Iran during June - September 2009 were investigated for STEC using PCR targeting stx1 and stx2 and then eaeA. Results: Of 206 samples, 36 (17.47%) were contaminated with STEC. STEC isolates harbored 56.41% and 43.59% stx2 and stx1 gene respectively. In antibiotic resistance test, all strains were sensitive to ceftazidime, cefepime, gentamicin, imipenem and ciprofloxacin. 23.08% of isolates were resistat to tetracycline, and 38.5% of them showed intermediate sensitvity to cephalothin. Conclusions: The high presence of STEC in raw milk confirms the important role of raw milk as putative vehicle of infection to human. Moreover, this study suggests that the development of antibiotic resistant STEC must be a major concern in Iran and more studies are needed to identify the prevalence of STEC in other food samples. [ABSTRACT FROM AUTHOR]

Published
2013

29. The Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: An Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique.

Author

Khademi F, Mohammadi P, and Mostafaei A

Subjects
Alternative Splicing, Animals, CHO Cells, Cell Survival drug effects, Cells, Cultured, Cricetulus, DNA, Complementary genetics, Humans, Leukocytes, Mononuclear drug effects, Polymerase Chain Reaction, RNA, Messenger genetics, Antibodies, Monoclonal pharmacology, Antigens, CD20 immunology, Immunoglobulin G immunology
Abstract

Despite the unparalleled success of anti-CD20-targeted immunotherapy, the currently available mAbs are not sufficiently efficacious in the treatment of lymphoma. 1F5 is one of a panel of anti-CD20 mAbs that was used in the B-cell lymphoma serotherapy. Despite the efficacy of murine 1F5 mAbs in lymphoma patients, the 1F5 chimeric antibodies with human effector functionality are yet to be approved and widely used in the treatment of lymphoma. In this study, the conversion of 1F5 mAb from mouse IgG2a to human-mouse chimeric IgG1 was achieved and the chimeric antibody was partially characterized. We constructed the 1F5 chimeric mouse-human anti-CD20 antibody genes using an efficient Splicing by overlap extension-polymerase chain reaction (SOE-PCR) technique and cloned the chimeric heavy and light genes in pBudCE4.1mammalian expression vector, followed by purification of the expressed chimeric 1F5 mAbs using affinity chromatography. Our investigation also included the biological properties of purified chimeric antibodies. The generated 1F5 chimeric mAbs mediate complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against Raji and Daudi Burkitt's lymphoma cell lines, which were comparable with rituximab and exhibit superior reduction in cell viability in vitro, compared to rituximab. The current study indicated that the generated chimeric 1F5 mAbs has potential CDC and ADCC activity which was comparable with rituximab whereas it exhibits a superior reduction in cell viability, compared to rituximab. Our work contributes to future studies involving in vivo biological functions and the application of the 1F5 chimeric antibody.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results